There is increasing evidence that platelets play an important role in the pathogenesis of acute ischemic heart disease. Therefore an understanding of factors that influence platelet performance is important. This study was undertaken (1) to characterize during evolving myocardial infarction platelet activity in the peripheral circulation and across the ischemic/infarcting myocardial compartment, the locus of presumed platelet hyperactivity, and (2) to evaluate the effects of prostacyclin (PGI2), a most potent antiplatelet agent and vasodilator. A total of 59 patients with evolving myocardial infarction were studied. Twenty-two patients were instrumented with arterial and coronary sinus catheters and received intravenous infusion of PGI2, 13 ± 4.5 ng/kg/min (mean ± SD), for 90 min. In 15 patients with anterior myocardial infarction, transcardiac platelet function and response to PGI2 were studied. Plasma levels of 8-thromboglobulin (/3-TG) and of thromboxane B2 (TxB2), in vivo measures of platelet activity, were elevated threeand 10-fold. 6-Keto-prostaglandin F,,, the stable end product of PGI2, was less than 10 pg/ml, reflecting a leftward shift of the TxB2/PGI2 ratio. Platelets circulating during evolving myocardial infarction ("ischemic platelets") were hyperaggregable in response to ADP and relatively resistant to PGI both in vivo and in vitro. Concentrations of platelet cyclic AMP and the cyclic AMP response to PGI2 were diminished. The platelet hyperreactivity, expressed by plasma 3-TG, platelet aggregation, and PGI2-induced inhibition of aggregation, was most intense early during infarct evolution and decreased with time. The increased platelet performance resulted in "platelet fatigue," indicated by decreased contents of ,3-TG of the ischemic platelet and decreased TxA2 production in response to collagen. However, the ischemic platelet produced twice normal TxA2 in response to arachidonic acid (stimulus and substrate), demonstrating a heightened metabolic capacity. TxA2 was produced across the ischemic/infarcting compartment in 10'of 15 patients with anterior myocardial infarction. The antiplatelet effect of PGI2 was greatly diminished. In summary, the data define an abnormal pattern of platelet behavior during evolving myocardial infarction, characterized by a proaggregatory environment, heightened platelet reactivity in both the peripheral and coronary circulation, and relative resistance to PGI2. The clinical consequences of the data are that the patient in the acute phase of myocardial infarction may benefit from suppression of platelet function and requires significantly greater doses of PGI2 than normal subjects. The data'also suggest future directions for therapeutic manipulation of platelet-hyperreactivity in the setting of acute myocardial ischemia.
gates in acutely occluded coronary vessels. 8' 9 In animal experiments, cyclical flow reduction by platelet aggregates proximal to the obstructive coronary lesion'1-2 and thromboxane formation distal to the obstruction have been observed." ' 12 These results have led to the suggestion that increased platelet activity and its consequences contribute to the development of unstable angina, acute myocardial infarction, and sudden cardiac death. ' 3 Therefore an understanding of platelet function and factors that influence platelet performance is important.
This study was undertaken to characterize both the platelets circulating during acute myocardial infarction and also local and systemic factors that might influence platelet behavior in this setting. Descriptors of platelet function in vivo, such as circulating release products, and platelet responsiveness in vitro to various stimuli were investigated and, whenever feasible, correlated in the attempt to characterize platelet behavior as completely as possible. Transcardiac alterations in platelet function across the ischemic/infarcting myocardial compartment were investigated, since this tissue bed is the locus of presumed platelet hyperactivity.
In addition to these empiric studies, the effect of a potent antiplatelet agent. prostacyclin (PGI2). on platelet behavior during acute myocardial infarction was evaluated. This prostaglandin is of interest for several reasons: first, it is considered the most potent antiaggregating agent yet described; second, it is synthesized by vascular endothelium and is postulated to provide endogenous biological protection against platelet microthrombi;'4 and third, it has a short serum half-life, making it an attractive agent for the treatment of patients with unstable coronary disease. From this study it was hoped that an approach to the manipulation of platelet function in acute myocardial infarction would emerge.
Methods
Patients. Two groups of patients with acute transmural myocardial infarction were studied: group I patients received only a peripheral venous line, and group II patients were instrumented with two intravascular catheters. Characteristics of the two groups are shown in table 1.
Criteria for acute myocardial infarction were (1) typical anginal pain for more than 30 min and (2) ST segment elevation greater than 1 mm in at least two leads in the extremity and/or precordial electrocardiogram. Myocardial infarction was confirmed retrospectively by serial creatine kinase-MB elevations.
In a third group of 20 normal volunteers, platelet activity was studied for comparison; 12 were men, and the average age was 43 + 10 years.
None of the patients or normal volunteers had taken aspirin or related drugs that might have interferred with the cyclooxygenase pathway during the previous 2 weeks. All patients had received sublingual or topical nitroglycerin, and most also had been given morphine in the emergency room. All patients received lidocaine as bolus and continuous intravenous infusion (2 mg/min) . Two patients in group I and one patient in group II had taken propranolol (not exceeding 10 mg tid), which was discontinued before the study. None of the patients had received calcium-channel blockers. None of the patients showed evidence of cardiac failure based on clinical findings and chest roentgenogram.
Procedure. The protocol was approved by the Institutional Review Board for Clinical Research, Montefiore Medical Center. All patients gave written informed consent.
In group I, blood was obtained by a single 19 gauge needle stick, with the first few milliliters discarded. Patients in group II were instrumented with an intra-arterial and a coronary sinus catheter: (1) a No. 6F catheter (USCI, Billerica, MA) was inserted via a femoral artery into the descending aorta in 14 patients, and a No. 20 gauge Angiocath (Deseret Medical Inc., Sandy, UT) was inserted via a radial artery in eight patients; (2) a No. 7F Baim catheter'5 (Electro-Catheter Co., Rahway, NJ) was inserted via the right internal jugular vein into the coronary sinus and advanced into the great cardiac vein. In seven of 15 patients in whom transcardiac platelet studies were performed, the catheters were coated with heparin (provided by supplier). The catheters were positioned in the coronary care unit by means of radiolucent beds and portable fluoroscopic equipment. They were flushed by a constant infusion pump with isotonic saline without heparin. A multichannel oscilliscope VR 6 (Electronics for Medicine) was used for recording. Measurements of arterial blood pressure, heart rate, and coronary'blood flow and blood samples were obtained at baseline, during the end of a 90 min infusion of PGI2, and 30 min after discontinuation of the infusion.
Plasma thromboxane B2 (TxB2) and ,3-thromboglobulin (13-TG) were determined from blood samples obtained under the following conditions: before instrumentation by venipuncture and shortly after through the catheter (n = 5), after approximately 40 (n = 5) and 90 min (n = 5), and simultaneously by venipuncture and through the catheter (n = 4). Specific methods. Thromboxane A2 (TxA2) and PGI2 in plasma were assayed by measuring the stable end products, TxB2 and 6-keto-prostaglandin F,, (6-keto-PGFI,a), with a radioimmunoassay kit (New England Nuclear RIA-NEK007/ 008). The method was modified by us16 as follows: To avoid falsely elevated TxB2 levels caused by the buffer matrix and nonspecific impurities introduced during the extraction procedure, we measured TxB2 directly in plasma without ethyl acetate extraction, and we used human plasma control, 0 ng/ml TxB2 (New England Nuclear) instead of 50 mM phosphate buffer. To increase the sensitivity, 20 pg of TxB2 or 6-keto-PGFI,, in human plasma control was added to duplicate specimens. Normal values were 7.3 + 6.9 (SD) pg/ml TxB2 and less than 10 pg/ml 6-keto-PGFI, (n 20). The reproducibility of 25 15 Inferior/posterior 12 7 Infarct size (CKMB g-Eq/m2) 44+±18 Norepinephrine and epinephrine in plasma were determined by high-pressure liquid chromatography (HPLC, Waters 6000A) with an LC-4 electrochemical detector.21 Standards containing 200 pg/ml of norepinephrine and epinephrine were run in parallel. Plasma contents in normal volunteers, obtained after 20 min rest in a supine position, were 168 + 41 pg/ml for norepinephrine and 47 + 14 pg/mI for epinephrine (n -13).
The coefficient of variation of 30 duplicate determinations was 2.1 -+-1.2% (norepinephrine) and 4.5 + 4.2% (epinephrine).
Platelet aggregation in response to ADP (Sigma Chemical Co.) and collagen (Bio Data Corp.) was measured by methods standard in our laboratory.22 In brief, blood was carefully drawn and transferred into polypropylene tubes containing 3.2% sodium citrate. This was then centrifuged at room temperature for 2 min 45 sec at 1000 g to obtain platelet-rich plasma (PRP). Platelet-poor plasma (PPP) was obtained by centrifuging the remaining pellet at 2200 g for 10 min at + 40 C. Platelet cell counts were determined in an ultraflow blood counter (Clay Adams), and final PRP concentration was adjusted to 250 to 400 x 106 platelets/ml with autologous PPP. Aggregometry was performed in a Payton dual-chamber aggregometer at 370 C with constant stirring (1000 rpm). Serial studies using various concentrations of ADP (0.5 to 8 ,uM) and of collagen (0.5 to 8 ,ug/ml) were done to generate dose-response curves. Results are expressed as aggregation to 50% (AG50; ,uM ADP or ,ug/ml collagen), indicating the amount of ADP or collagen required to achieve 50% change in optical density. Normal values averaged 1.46 + 0.35 p.M ADP (n = 20) and 1.26 + 0.53 ,ug/ml collagen (n = 11). Total time from initial phlebotomy to aggregation was greater than 30 min, and all studies were performed within 120 min. Duplicate studies were done at the beginning and end of this study interval to verify internal consistency. Inhibiton of platelet aggregation (INH50): Maximal aggregation in response to ADP was determined as described above. PRP was exposed in the aggregometer to varying concentrations of PG12 (0.5 to 4 ng/ml) for 3 min, followed by addition of 4 p.M ADP, and aggregation was determined. Results are expressed as inhibition to 50% (INH50; ng/ml PG12), indicating the amount of PG12 required to inhibit the maximal change in optical density by 50%. /3-TG release was measured after 5 min exposure to ADP (0.5 to 8 ,uM) or collagen (0.5 to 8 ,ug/ml) in the aggregometer under the conditions described above. Release of f3-TG was stopped by the addition of 10 , M PGE1 and 8 p.M indomethacin. The specimen was subsequently centrifuged at 9000 g for 2 min and the supernatant diluted in saline buffer containing 10 juM PGE, and 8 p.M indomethacin. 18-TG was assayed with an Amersham radioimmunoassay kit (see above). Normal values averaged 34 + 8.7 gg/109 platelets after ADP exposure (n = 15) and 37 + 10 gg/109 platelets after collagen exposure (n 10). Platelet Normal values were 44 + 9.3 .ug/109 platelets (n = 15). 1338 Platelet thromboxane production was determined according to the method of Ludlam et al. 24 Briefly, samples of PRP were stimulated in the aggregometer as described above with 50 to 500,ug/ml arachidonic acid (AA), (Bio Data Corp) for 8 min or with 0.5 to 8,ug/ml collagen for 5 min and then centrifuged at 900 g for 2 min. A 50 p1l aliquot of supernatant was then transferred into phosphate buffer containing 10 p.g/ml diclofenac sodium. TxB2 contents were measured as indicated above with the exception that phosphate buffer was used as a matrix system. Results are expressed as maximum TxA2 production; normal values were 2.5 + 0.9 ng/107 platelets after arachidonic acid exposure to AA (n = 20) and 1.0 + 0.35 ng/107 platelets after collagen (n = 10).
Cyclic AMP (cAMP) contents in PRP alone and in PRP exposed to 1 ng/ml PG12 at 370 C for 3 min in the aggregometer were measured by a standard radioimmunoassay kit (DuPont, NEK-0033) modified by us as follows: PRP after stimulation was precipitated with equal volumes of 10% trichloroacetic acid, centrifuged at 9000 g for 2 min, and the supematant washed four times with fivefold excess volume of ether. The aqueous phase was dried under nitrogen and the residue was resuspended in 1 ml of sodium acetate (0. CIRCULATION PGI2 was kindly provided by Upjohn Co., Kalamazoo, MI. Intravenous infusion of PGI2 was begun at 2 ng/kg/min and increased at 3 min intervals at increments of 2 ng/kg/min. Limiting end points for the infusion were: (1) increase in heart rate of 20% of baseline and/or absolute heart rate greater than 115 beats/min, (2) decrease in mean arterial pressure of 20% below baseline and/or absolute mean blood pressure less than 65 mm Hg, (3) side effects such as nausea, vomiting, headache, or excess anxiety. The maximum dose tolerated by patients with myocardial infarction for 90 min was 13 4.5 ng/kg/min. Data analysis. Statistical analysis was performed with Student's t test for paired and unpaired data. Data with three study points on the same patient were compared by analysis of variance.26 A p value <.05 was considered significant. Data were expressed as mean 1 SD. To reduce the impact of the skewness of the original thromboxane levels in the artery and great cardiac vein on test statistics, which assumes some degree of normality, and to adjust for the exaggeration of the impact of small negative great cardiac vein-arterial differences with large arterial levels (see below), we used percent change and log transformation of the data. Statistical significance of the log of the ratios was calculated by t test. The use of the log and reciprocal functions for calculating relationships between time and the measurements for AG50, INH50, and plasma ,8-TG concentration was based on analyzing several different types of data transformation and displaying those that provided the best linear fit.
Results

Platelet function in peripheral blood
Group I (not instrumented). Data figure 1 . Maximal TxA2 production in response to AA is twice as high in the infarct group compared with normal. cAMP concentrations in PRP are lower in patients with, infarction vs normals and remain lower in response to 1 ng/ml PGI2.
Vol. 72, No. 6, December 1985 cantly elevated compared with normal. Plasma contents of 6-keto-PGFla (not shown) averaged less than 10 pg/ml in both groups. Thus the TxB2/PGI2 ratio was shifted toward thromboxane. The platelets circulating in the acute phase of infarction ("ischemic platelets") were highly aggregable: significantly less ADP was required for 50% aggregation compared with normal. Furthermore, the ischemic platelets were relatively resistant to PGI2; twice the amount of PGI2 was required for inhibition of aggregation by 50%. Concentrations of cAMP, a biochemical mediator for the inhibitory effect of PGI2 on aggregation, were decreased in the PRP of patients with infarction compared with normals. PGI2 (1 ng/ml) increased the cAMP concentrations to 10 (p < .001) and 14 (p = .001) pmol/108 platelets, respectively. The PGI2-induced changes were similar in both groups, although the maximal cAMP levels in the infarct group remained lower than in normal subjects. The maximal thromboxane production by the ischemic platelet in response to AA was twice that of normal. Separation of the platelet function data described above according to anterior/lateral (AMI, n = 25) and inferior/posterior infarction (IMI, n = 12) showed no statistically significant differences between the two subgroups: plasma contents averaged for /3-TG, 121 ± 56 (AMI) and 107 ± 74 (IMI) ng/ml; for TxB2, 73 ± 62 and 82 ± 59 pg/ml; for AG50, 0.88 ± 0.28 and 0.93 ± 0.37 ,M ADP; for INHso, 1.79 ± 0.93 and 1.98 ± 1.69 ng/ml PGI2; for maximal TxA2 production, 4.38 ± 1.64(n = 19) and4.70 ± 1.24(n = 11) ,ug/ml AA.
In order to evaluate the impact of the increased release of /3-TG and production of thromboxane in vivo on the functional capacity of the ischemic platelet, we studied the platelet response to maximal stimulation in vitro (table 2). In response to collagen, the production of thromboxane was reduced by 46% compared with normal. However, if AA was used as stimulus (and substrate) (figure 2), the ischemic platelet produced twice as much thromboxane as the normal. Platelet ,8-TG contents of the ischemic platelet were half of normal. Maximal /3-TG release in response to collagen approximated 80% in both groups. The amounts released averaged 17 and 37 ,ug/109 platelets. Group II (instrumented with two catheters). Baseline before catheter placement and shortly afterwards throuj (00), after 40 min (AA), after 90 min (VY), and sim venipuncture and through the catheter (aE). Results do n differ over a period of up to 90 min or when sampled sim particular, there is no consistent increase in plasma cor tributable to catheter exposure. The distribution of data p above and below the line of identity.
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TG from blood samples obtained before placement of in vitro (mean catheters and shortly after through the catheter, after approximately 40 and 90 min, and simultaneously by p value venipuncture and through the catheter. The distribution of the data points is similar above and below the line of identity. The mean values for TxB2 are 69 + 37 (venipuncture) and 65 + 38 pg/ml (catheter) and those Inhibition of aggregation by PGI, was least effective in the early infarct phase and improved with infarct dura- (15) <.001 tion ( figure 6, B FIGURE 4 . Arterial-great cardiac vein differences in plasma levels of TxB2 and ,3-TG. Dotted lines represent data obtained with heparincoated catheters. In two-thirds of the patients, TxB2 levels in the great cardiac vein are twofold to threefold higher. There is no difference in the transcardiac 83-TG levels, except in one patient. tents of 6-keto-PGFi, the stable metabolite of PGI2. The agent decreased plasma ,3-TG and reduced platelet aggregation; the amount of ADP required for 50% aggregation doubled. These PGI2-induced changes were reversible after termination of the infusion. PGI2 tended to decrease plasma TxB2 levels; however, the responses varied widely. Plasma levels of norepinephrine and epinephrine remained unchanged during the infusion.
We evaluated the effect of prostacyclin on platelet reactivity across the infarcting compartment. Data are reported as ratios of great cardiac vein/arterial contents (figure 5). During infusion of PGI2, the TxB2 ratios decreased in six of the eight "thromboxane producers" Vol. 72, No. 6, December 1985 receiving the agent; the ratios remained essentiallv unchanged in four patients and increased in two. The mean values of the ratios of the entire group were 2.2 and 1.5 (NS); the geometric mean values were 1.85 and 1.38 (NS), respectively. The great cardiac vein/arterial ratios for ,f-TG ( figure 5) were distributed essentially around unity at control measurements and during infusion of PGI2. The mean values were 1. 1 and 1.2. Blood flow in the great cardiac vein remained essentially unchanged during administration of PGI2: 62 ± 23 ml/min before and 66 ± 26 ml/min during the infusion, excluding a dilutional effect on the transcardiac PGI2 and f3-TG values.
Discussion
Our data clearly demonstrate enhanced platelet reactivity during the early hours of myocardial infarction. In vivo, release of 1-TG and formation of thromboxane are increased, and the relationship between thromboxane and PGI2 is strikingly shifted in favor of thromboxane. In vitro, platelet aggregation in response to exogenous stimuli is enhanced. The ADP dose-response curve of the ischemic platelets is left shifted when contrasted with normal. The alteration in platelet behavior in patients with acute myocardial infarction is also marked by a reduced response to exogenous (and probably to endogenous) PGI2. In vivo, infusion of 10 to 20 ng/kg/min PGI2 increases the required amount of ADP for 50% aggregation from 1.1 to only 2.1 ,M, in contrast to normal volunteers27 in whom infusion of 10 to 12 ng/kg/min increased the required ADP from 1.8 to 4.5 ,M. In vitro, twice the amount of PGI2 is required to inhibit platelet aggregation by 50%. Similarly, concentrations of cAMP, a biochemical mediator for the antiaggregatory effects of PGI2, are lower in the ischemic platelet compared with normal and remain lower after exposure to PGI2 in vitro.
These results in patients with acute myocardial infarction and endogenously elevated catecholamines support previous observations by us28 and others29 30 that catecholamines change the platelet response to PGI2, presumably by altering the bioavailability of platelet membrane receptors.3'-3 Using platelets from normal volunteers, we have shown28 that subaggregatory doses of epinephrine and norepinephrine abolish the inhibitory effect of PGI2 on aggregation and also the cAMP increase in response to PGI2. a-Adrenergic blockade reestablishes both PGI2 effects.
The platelet hyperreactivity in vivo is reflected by alterations of the metabolic capacity of the ischemic platelet as studied in vitro. We realize that in vitro tests may not accurately represent actual physiologic condi- tioning release pathway but has undergone partial adegranulation. Furthermore, maximal thromboxane formation by the ischemic platelet in response to collagen is decreased by 46%, whereas AA, providing both stimulus and substrate, elicits twice as much throtnboxane formation as control. These data emphasize that the ischemic platelet has a heightened metabolic capacity that may, at least in vitro, be dampened by limited substrate availability. Consistent with these results are studies in experimental myocardial infarction demonstrating an accumulation of malondialdehyde,34 a breakdown product of AA, and decreased concentrations of phospholipids in the infarcting myocardium.35
The clinical relevance of these data is unclear, since the potential substrate limitation does not seem to interfere with enhanced platelet performance. That ischemic platelets remain hyperaggregable in the face of reduced thromboxane formation may imply that additional pathways of platelet aggregation are activated during myocardial ischemia3638 and that antiplatelet therapy aimed only at the cyclooxygenase pathway (such as aspirin) may be less effective than combination therapy in suppressing platelet hyperactivity. Furthermore, it is conceivable that compounds such as TxA2, serotonin, 2, 19 and catecholamines'2 2 remain bound to their respective receptors after removal of platelets from the circulation, contributing to the hyperaggregability of the ischemic platelets. When platelet activity is related to infarct duration, it is evident that the most striking alterations are seen early after onset of infarction. Aggregation (figure 6, A) is most abnormal in the hyperacute phase and tends to normalize as time from clinical onset increases although aggregation remains abnormal. Inhibition of aggregation ( figure 6, B) is least effective in the hyperacute infarct phase and improves with time. Plasma contents of 13-TG, an in vivo indicator of platelet activity, are highest early after onset of infarction and decline with increasing infarct duration. Whether or not these early changes in platelet activity have biological significance in triggering or contributing to infarction cannot be answered by our results. An important caveat is that our patients were studied relatively late after onset of infarction, making it impossible to-distinguish primary events from those secondary to infarction and tissue damage. However, if tissue damage were responsible for platelet hyperactivity, one might predict an increase rather than a decrease in platelet activity with time. Our data suggest that platelet reactivity is enhanced across the infarcting myocardial compartment. Throm-Vol. 72, No. 6, December 1985 boxane is produced across the coronary circulation in two-thirds of patients with evolving anterior wall infarction. The reason that this response is not universal is unclear, and no factor can be identified that predicts thromboxane production. Plasma catecholamine contents are elevated in both groups, there is no consistent transcardiac catecholamine increase in the thromboxane producers, and time from onset of infarction to study and size of infarct are not different among groups. We cannot demonstrate transcardiac release of ,B-TG, in contrast to thromboxane, perhaps because the amount released at the infarct site is insufficient to influence the high serum concentrations given the long half-life of the compound. It is also possible that agranule function is exhausted in the ischemic compartment, since' release is independent of thromboxane production43 and responds to less potent stimulation. 43 4 Transcardiac formation of thromboxane in patients with acute myocardial infarction has been reported previously, although results have varied.11'45'-4 Hirsh et al.4546 have shown that thromboxane is produced in patients with unstable angina or recent mnyocardial infarction but not in patients with stable angina, suggesting that the dynamic character of the coronary lesion may be important. Autopsy studies in patients with sudden cardiac death have identified layers of thrombus of different ages and platelet thrombi in occluded coronary vessels. 9 There is concern that platelets might be activated by catheter placement, exposure over time, and blood sampling. 49 Our data indicate that catheter-induced platelet activation is unimportant in patients with increased platelet activity before instrumentation. As demonstrated in figure 3 , plasma contents of TxB2 and B3-TG do not significantly differ when obtained before and after catheter placement over a period of up to 90 min, or simultaneously by venipuncture and through the catheter. In particular, there is no consistent increase over time. The distribution of the data points is similar above and below the line of identity. Other investigators50 have failed to show consistent alterations in platelet activity attributable to catheter exposure. Furthermore, we have established the platelet function profile in a matched group of patients with acute myocardial infarction without instrumentation, and the data of the instrumented infarct group are similar to the data of this group.
Intravenous infusion of PGI2 to patients with evolving myocardial infarction produces an attenuated antiplatelet effect. Patients with infarction tolerate higher doses of PGI2 ( 10 to 20 ng/kg/min) over a longer period 1343 IP~~-of time than either normal volunteers5"-" or cardiac patients without acute myocardial ischemia (8 to 12 ng/kg/min). 27 54 The few studies using higher doses report infusions of only 10 to 15 min.5556 In spite of the higher doses of PGI2, the inhibitory effect on platelet aggregation is small. At an equivalent infusion rate of 10 to 12 ng/kg/min, the rightward shift of the ADP dose-response curve of the patients with infarction is only 20% of the shift observed in normal volunteers.51 These data obtained during intravenous infusion of PGI2 support the results in vitro discussed above in which PGI2 added to PRP of patients with evolving myocardial infarction has an attenuated inhibitory effect on aggregation of ischemic platelets in vitro. The PG12-induced decrease in plasma ,3-TG (table 3) is moderate, and there is no effect on coronary sinus f-TG levels. PGI2 does not consistently affect peripheral or transcardiac TxB2 concentrations.
In summary, we have defined a pattern of abnormal platelet behavior in the acute phase of myocardial infarction. This is characterized by a proaggregatory environment (elevated thromboxane-to-PGI1 ratio in both systemic and coronary circulation), evidence of heightened platelet activity in vivo (increased circulating ,3-TG) and increased platelet aggregability in vitro.
Platelets from patients with myocardial infarction are relatively resistant to the antiaggregatory effects of exogenous PGI2. These data and the finding that the platelet abnormalities are most striking in the hyperacute phase of infarction support the contention that platelet aggregation and thrombus formation are important participants in the events of acute myocardial ischemialinfarction.
On the basis of the characterization of the platelet abnormalities, acknowledging the limitations that our patients were studied relatively late after onset of infarction and not allowing a separation of primary from secondary events, future directions for the manipulation of platelet hyperactivity in acute myocardial infarction can be suggested. Conventional antiplatelet agents and PGI, are probably insufficient by themselves to influence the proaggregatory environment. Alternative approaches would include agents that decrease the release of catecholamines and thus ameliorate their synergistic effects on endogenous inducers of platelet activity, 12 4042 agents that block the platelet a2adrenergic receptors so as to make platelets more responsive to the antiaggregatory effects of PGI2,2'-30 agents that potentiate the effect of PGI2 such as phosphodiesterase inhibitors,57 and agents that reduce the effect of thromboxane such as thromboxane synthetase inhibitors or thromboxane receptor antagonists.'-2 39 The recognition that the event of myocardial infarction likely involves dynamic thrombus formation, in which both platelets and plasma proteins participate, and that the ischemic platelet has a heightened sensitivity to these plasma constituents might suggest use of both antiplatelet and anticoagulant modalities.
